Small Dense Low Density Lipoprotein Has Increased Affinity for LDL Receptor-independent Cell Surface Binding Sites: a Potential Mechanism for Increased Atherogenicity
Overview
Affiliations
Small dense low density lipoprotein (LDL) particles have altered apolipoprotein (apo) B conformation and lowered affinity for the LDL receptor (J. Biol. Chem. 1994. 269: 511-519). Herein, we examine the interaction of small dense LDL with cell LDL receptor-independent binding sites. Compared to normal LDL, at low LDL cell media concentrations (<10 microg/ml), small dense LDL had decreased specific binding to the LDL receptor on normal fibroblasts at 4 degrees C, but a 2-fold increased binding to LDL receptor-independent cell sites. At higher LDL concentration (100 microg/ ml), LDL receptor-independent binding of small dense LDL was 4.5-fold that of normal LDL in normal fibroblasts, but greater (2- to 14- fold) in LDL receptor-negative fibroblasts. In LDL receptor-negative fibroblasts at 37 degrees C, small dense LDL had higher (3-fold) cell association than normal size LDL but no effective LDL degradation. At high LDL concentrations (> or =100 microg/ml), LDL binding to normal or LDL receptor-negative fibroblasts was not affected by several anti-apoB monoclonal antibodies or by cell pretreatment with proteases, chondroitinase, or neuraminidase. In contrast, pretreating normal and receptor-negative fibroblasts with heparinase and heparitinase decreased LDL cell binding by 35% and 50%, respectively. Similarly, preincubation of receptor-negative fibroblasts with sodium chlorate, an inhibitor of proteoglycan sulfation, decreased LDL binding by about 45%. We hypothesize that small dense LDL might be more atherogenic than normal size LDL due to decreased hepatic clearance by the LDL receptor, and enhanced anchoring to LDL receptor-independent binding sites in extrahepatic tissues (e.g., the arterial wall), a process mediated, in part, by cell surface proteoglycans.
Assempoor R, Daneshvar M, Taghvaei A, Abroy A, Azimi A, Nelson J Cardiovasc Diabetol. 2025; 24(1):35.
PMID: 39844262 PMC: 11756160. DOI: 10.1186/s12933-025-02582-2.
Hirano T J Diabetes Investig. 2025; 16(3):370-383.
PMID: 39778086 PMC: 11871407. DOI: 10.1111/jdi.14398.
Desjardins L, Briere F, Tremblay A, Rancourt-Bouchard M, Drouin-Chartier J, Corbeil J Am J Clin Nutr. 2024; 119(5):1270-1279.
PMID: 38518848 PMC: 11130675. DOI: 10.1016/j.ajcnut.2024.03.015.
A novel assay to measure low-density lipoproteins binding to proteoglycans.
Geh E, Swertfeger D, Sexmith H, Heink A, Tarapore P, Melchior J PLoS One. 2024; 19(1):e0291632.
PMID: 38295021 PMC: 10830033. DOI: 10.1371/journal.pone.0291632.
Okamura T, Tsukamoto K, Arai H, Fujioka Y, Ishigaki Y, Koba S J Atheroscler Thromb. 2023; 31(6):641-853.
PMID: 38123343 PMC: 11150976. DOI: 10.5551/jat.GL2022.